The molecular background of mucinous carcinoma beyond MUC2
N Hugen, M Simons, A Halilović… - The Journal of …, 2015 - Wiley Online Library
The increasing interest of the oncology community in tumour classification and prediction of
outcome to targeted therapies has put emphasis on an improved identification of tumour …
outcome to targeted therapies has put emphasis on an improved identification of tumour …
[HTML][HTML] Recommendations for diagnosing STIC: a systematic review and meta-analysis
JMA Bogaerts, MP Steenbeek, MHD van Bommel… - Virchows Archiv, 2022 - Springer
Our understanding of the oncogenesis of high-grade serous cancer of the ovary and its
precursor lesions, such as serous tubal intraepithelial carcinoma (STIC), has significantly …
precursor lesions, such as serous tubal intraepithelial carcinoma (STIC), has significantly …
[HTML][HTML] Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant …
H Westdorp, JHA Creemers, IM van Oort… - … for immunotherapy of …, 2019 - Springer
Background Clinical benefit of cellular immunotherapy has been shown in patients with
castration-resistant prostate cancer (CRPC). We investigated the immunological response …
castration-resistant prostate cancer (CRPC). We investigated the immunological response …
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas
RDA Weren, AR Mensenkamp, M Simons… - Human …, 2017 - Wiley Online Library
With the recent introduction of Poly (ADP‐ribose) polymerase inhibitors, a promising novel
therapy has become available for ovarian carcinoma (OC) patients with inactivating BRCA1 …
therapy has become available for ovarian carcinoma (OC) patients with inactivating BRCA1 …
Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition
Background Women with epithelial ovarian cancer (OC) have a higher chance to benefit
from poly (ADP-ribose) polymerase inhibitor (PARPi) therapy if their tumor has a somatic or …
from poly (ADP-ribose) polymerase inhibitor (PARPi) therapy if their tumor has a somatic or …
[HTML][HTML] Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer
YHW Derks, M Rijpkema, HIV Amatdjais-Groenen… - Theranostics, 2021 - ncbi.nlm.nih.gov
Incomplete resection of prostate cancer (PCa) occurs in 15%-50% of PCa patients. Disease
recurrence negatively impacts oncological outcome. The use of radio-, fluorescent-, or …
recurrence negatively impacts oncological outcome. The use of radio-, fluorescent-, or …
[HTML][HTML] A national population-based study provides insight in the origin of malignancies metastatic to the ovary
J Bruls, M Simons, LI Overbeek, J Bulten, LF Massuger… - Virchows Archiv, 2015 - Springer
A significant proportion of ovarian malignancies consists of metastatic tumors, with a wide
variety in site of origin. Differentiating between a primary and metastatic malignancy of the …
variety in site of origin. Differentiating between a primary and metastatic malignancy of the …
Two types of primary mucinous ovarian tumors can be distinguished based on their origin
M Simons, F Simmer, J Bulten, MJ Ligtenberg… - Modern …, 2020 - nature.com
The origin of primary mucinous ovarian tumors is unknown. We explore the hypothesis that
they originate from either Brenner tumors or teratomas and examine differences between the …
they originate from either Brenner tumors or teratomas and examine differences between the …
[HTML][HTML] Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
YHW Derks, MGM Schilham, M Rijpkema… - European Journal of …, 2023 - Springer
Purpose Incomplete resection of prostate cancer (PCa) results in increased risk of disease
recurrence. Combined fluorescence-guided surgery with tumor-targeted photodynamic …
recurrence. Combined fluorescence-guided surgery with tumor-targeted photodynamic …
Relatively poor survival of mucinous ovarian carcinoma in advanced stage: a systematic review and meta-analysis
M Simons, L Massuger, J Bruls, J Bulten… - International Journal of …, 2017 - ijgc.bmj.com
Objective Overall, patients with mucinous ovarian carcinoma (MOC) are considered to have
a better prognosis compared with the whole group of nonmucinous carcinomas. However …
a better prognosis compared with the whole group of nonmucinous carcinomas. However …